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Abstract Osteoarthritis (OA) is a degenerative diseasewhich causes pain and stiffness
in joints. OA progresses through excessive degradation of joint cartilage, eventually
leading to significant joint degeneration and loss of function. Cytokines, a group of cell
signalling proteins, present in raised concentrations in OA joints, can be classified into
pro-inflammatory and anti-inflammatory groups. They mediate cartilage degradation
through several mechanisms, primarily the up-regulation of matrix metalloproteinases
(MMPs), a group of collagen-degrading enzymes. In this paper we show that the inter-
actions of cytokines within cartilage have a crucial role to play in OA progression
and treatment. We develop a four-variable ordinary differential equation model for
the interactions between pro- and anti-inflammatory cytokines, MMPs and fibronectin
fragments (Fn-fs), a by-product of cartilage degradation and up-regulator of cytokines.
We show that the model has four classes of dynamic behaviour: homoeostasis, bistable
inflammation, tristable inflammation and persistent inflammation. We show that posi-
tive and negative feedbacks controlling cytokine production rates can determine either
a pre-disposition to OA or initiation of OA. Further, we show that manipulation of
cytokine, MMP and Fn-fs levels can be used to treat OA, but we suggest that multiple
treatment targets may be essential to halt or slow disease progression.
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1 Introduction
Osteoarthritis (OA) is a degenerative disease of the joints and is a leading cause
of disability worldwide. Characterised by pain and stiffness in joints, OA leads to
a significant loss of mobility. OA is strongly correlated with increasing age, with
estimates that OA affects as many as 80% of those over 75years of age (Arden and
Cooper 2005). Other major risk factors include genetic predisposition, obesity, and
injury or trauma to the joint (Felson et al. 2000). Recent research has also implicated
inflammatory processes in the pathogenesis and progression of OA (Hedbom and
Huselmann 2002; Scanzello and Goldring 2012).
The main disease mechanism in OA is the degeneration of the cartilage lining the
joint. This allows the bone ends to rub together and eventually the whole joint is
compromised and breaks down. Onset of OA varies between individuals and can be
fast, known as acute onset OA. Typically, however, the onset will be gradual, with
sporadic periods of symptoms followed by asymptomatic periods for several years as
the condition progresses.
Despite a desperate need for disease-modifying treatments for OA, currently none
have progressed beyond clinical trials (Roubille et al. 2015), and only pain-relieving
treatments are available. There is a need for research into effective treatment in early
OA to slow the progression of the disease.
Initiation ofOA is the loss of the homoeostatic balance between extracellularmatrix
(ECM) synthesis and degradation (Sandell and Aigner 2001). Cartilage breakdown is
accelerated through raised pro-inflammatory cytokine levels, stimulating production
of matrix metalloproteinases (MMPs), which degrade the tissue (Martel-Pelletier et al.
2008). This degradation includes fibronectin breakdown and waste fibronectin frag-
ments (Fn-fs) act as an irritant stimulating further pro-inflammatory cytokine response
(Martel-Pelletier 2004). Pro-inflammatory cytokines and Fn-fs also induce production
of anti-inflammatory cytokines offsetting some of this activity.
To date there are few published mathematical models of cytokine interactions
specifically in OA but models which consider cartilage lesions, cytokine networks
and inflammation may be relevant. A model of articular cartilage lesion formation and
recovery (Wang et al. 2015; Graham et al. 2012), showed that in healthy tissue the
balance of pro- and anti-inflammatory signalling is the determining factor in returning
the system to homoeostasis after a blunt force injury. The model we present here also
considers this balance but focuses on behaviour when the balance is lost. A model
of acute systemic inflammation as a result of pathogen infection was presented by
Kumar et al. (2004). The model identified five possible outcomes of infection some of
which seem similar to those present in OA, particularly healthy response and recur-
rent inflammation. A general model of inflammation was proposed by Herald (2010)
considering macrophage-mediated inflammation. The model showed that even small
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cytokine-dependent inflammatory responses to infection may become chronic rather
than being resolved.
Two key models of cytokine signalling may be relevant to OA. One is a model
of the dynamics of IL-1, TNF-α and IL-10 in monocytes (Seymour and Henderson
2001). The model showed different types of behaviour dependent upon the parameter
values, including uncontrolled production of IL-1, stable equilibria and stable limit
cycles which the authors linked to observed behaviour in RA and Septic Shock. A
related model by Jit et al. (2005) looked in more depth at pro-inflammatory TNF-α
and modelled the effects of anti TNF-α drugs in the inflamed synovial joint. From
the model results the authors suggested that cytokine levels in RA were usually in
equilibrium and anti TNF-α forced a shift from a disease equilibrium to a healthy
equilibrium. However, they suggested that SIRS was a non-equilibrium condition and
as such could not be moved to a healthy equilibrium state. A model of epithelium
homoeostasis by Domínguez-Hüttinger et al. (2013) shows the importance of positive
and negative feedback in homoeostatic regulation of inflammation.
We have previously published a two-variable ODEmodel analysing the interactions
of cytokines (Baker et al. 2013) classified into two groups, pro- and anti-inflammatory.
We showed that the feedback mechanisms gave rise to monostable and bistable
behaviour, which we were able to associate with disease processes within the RA
synovium. We suggested possible mechanisms of disease progression in RA as well
as implications for treatment strategies. In that previousmodel we considered cytokine
dynamics in isolation. However, we know that in OA other factors such as mechanical
damage can lead to OA initiation and progression. Given that anti-cytokine therapies
have so far proved unsuccessful in OA we suggest that not only the cytokine network
but its relationship to other factors in OA, such as the waste products of joint dam-
age, may be crucial in perpetuating the feedback networks leading to disease. For this
reason, we extend this previous model to include MMPs and Fn-fs and investigate the
interactions between these variables.
In the following section, we describe the model development,
non-dimensionalisation and analysis of the steady states of the system.We also look at
parameter sensitivity. In Sect. 3 we conduct a bifurcation analysis of the model, which
shows the range of behaviours in the model which we classify based on the nature and
stability of the steady states. In Sect. 4, we look at possible treatment strategies for
the categories of behaviour observed in the bifurcation analysis. Finally, in Sect. 5, we
discuss the main findings of the model and their implications.
2 Model equations and steady state analysis
Our four model variables are pro-inflammatory cytokines (p), anti-inflammatory
cytokines (a), MMPs (m) and Fn-fs ( f ). The network of interactions between these
variables is shown in Fig. 1 and is based on the joint and cytokine biology as described
inWojdasiewicz et al. (2014), Fernandes et al. (2002), Goldring (2000b) andWestacott
and Sharif (1996).
Pro-inflammatory cytokines are normally present at low levels in the cartilage as
they play a role in mediating the normal turnover of the ECM (Poole 1993), which
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Fig. 1 A simplified network of cytokine interactions within articular cartilage. Cytokines are classed as
either pro- or anti-inflammatory. MMPs directly degrade the ECM leading to the release of fibronectin
fragments (Fn-fs). Fn-fs are an irritant leading to an increased cytokine response
involves remodelling the cartilage ECM at a very slow rate to maintain tissue integrity.
Production of pro-inflammatory cytokine is up-regulated in response to trauma or
infection, as part of the inflammatory response and repair mechanism. This response
is usually kept in homoeostatic balance by anti-inflammatory cytokines, which act
both to inhibit the synthesis of pro-inflammatory cytokines and also to block pro-
inflammatory cytokine receptors (Opal and DePalo 2000). To model these processes
we assume that production of pro-inflammatory cytokines, p, is dependent on itself,
anti-inflammatory cytokines, a, and Fn-fs, f ,
dp
dt
=
(
c0 + c1 p
n
c2n + pn + c3
f n
c4n + f n
)(
c5n
c5n + an
)
− dp p. (1)
We assume that production rates will be limited biologically and therefore model
functions of p, a and f as saturating Hill functions with Hill coefficients, n. For sim-
plicity in Eq. 1 and the following we assume equal Hill coefficients in all regulatory
Hill functions. In the discussion we consider the implications of unequal Hill coeffi-
cients. We also assume that pro-inflammatory cytokines will degrade naturally at rate
dp. We choose to make the stimulatory terms additive since these two pathways are
biochemically distinct and activate different cell receptors. This means that even if
there is no cartilage degradation there may still be a large cytokine response due to an
increase in p. Since anti-inflammatory cytokines reduce production and effectiveness
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of pro-inflammatory cytokines regardless of the sourcewe apply the anti-inflammatory
inhibition term to all the source terms.
Anti-inflammatory cytokine production is stimulated by both pro-inflammatory
cytokines and fibronectin fragments. The dynamics of anti-inflammatory cytokines, a,
therefore includes source terms (saturatingHill functions of p and f ) representing their
up-regulation by both pro-inflammatory cytokines and Fn-fs, and a natural degradation
term,
da
dt
= c6 p
n
c7n + pn + c8
f n
c9n + f n − daa. (2)
MMPs mediate ECM degradation and the synthesis of MMPs is stimulated by pro-
inflammatory cytokines (Vincenti and Brinckerhoff 2002). MMPs are also found at
low levels in normal cartilage so we assume some basal production. Together with
natural degradation, the dynamics of MMPs (m) are therefore modelled by
dm
dt
= c10 + c11 p
n
c12n + pn − dmm. (3)
We model Fn-fs production as a result of ECM degradation at a rate proportional
to the MMP level, m, with an additional constant rate c14 representing mechanical
damage. We also include natural degradation, giving
d f
dt
= c13m + c14 − d f f. (4)
We non-dimensionalise the model using the scalings:
p = c2 p˜ a = c5a˜ m = m˜c4da
c13
f = c4 f˜ t = t˜
da
where the tilde denotes dimensionless quantities. Time is scaledwith the degradation of
anti-inflammatory cytokines, which we expect to be in the order of minutes. Dropping
the tildes for convenience gives the dimensionless model:
dp
dt
=
(
Pbp + Ppp p
n
1 + pn + Pf p
f n
1 + f n
)(
1
1 + an
)
− γp p (5)
da
dt
= App p
n
Aphn + pn + A f p
f n
Anf h + f n
− a (6)
dm
dt
= Mbp + Mpp p
n
Mphn + pn − γmm (7)
d f
dt
= m + Fdam − γ f f (8)
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where,
Pbp = c0
c2da
, Ppp = c1
c2da
, Pf p = c3
c2da
, App = c6
c5da
,
Aph = c7
c2
, A f p = c8
c5da
, A f h = c9
c4
, Mbp = c10c11
c4da2
,
Mpp = c11c13
c4da2
, Mph = c12
c2
, Fdam = c14
c4da
, γp = dp
da
,
γm = dm
da
, γ f = d f
da
.
The meaning of each of these new parameters is summarised in Table 1.
Insight into the nature of the steady states of this system can be gained from the
nullclines, which are hypersurfaces given by
p˙ = 0 ⇐⇒ a =
(
1
γp p
(
Pbp + Ppp p
n
1 + pn + Pf p
f n
1 + f n
)
− 1
) 1
n
, (9)
Table 1 The parameters in the system (5)–(8), their interpretation and the reference values used throughout
the paper
Parameter Description Value
Pbp Background pro-inflammatory production 0.01
Ppp Pro-inflammatory cytokine driven pro-inflammatory cytokine
production
10
Pf p Fibronectin fragment driven pro-inflammatory cytokine production 10
App Pro-inflammatory cytokine driven anti-inflammatory cytokine
production
10
Aph Pro-inflammatory cytokine concentration at which
pro-inflammatory cytokine driven anti-inflammatory cytokine
production is half maximal
1
A f p Fibronectin fragment driven anti-inflammatory cytokine production 10
A f h Concentration at which Fibronectin fragment driven
anti-inflammatory cytokine production is half maximal
1
Mbp Background MMP production 0.01
Mpp Pro-inflammatory cytokine driven MMP production 10
Mph Pro-inflammatory cytokine concentration at which MMP
production is half maximal
1
Fdam Mechanical damage parameter 0
γp Relative rate of clearance of pro-inflammatory cytokine to
anti-inflammatory cytokine
1
γm Relative rate of clearance of MMP to anti-inflammatory cytokine 1
γ f Relative rate of clearance of fibronectin fragments to
anti-inflammatory cytokine
1
n Hill coefficients of regulatory Hill functions 2
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a˙ = 0 ⇐⇒ a = App p
n
Anph + pn
+ A f p f
n
Anf h + f n
, (10)
m˙ = 0 ⇐⇒ m = Mbp
γm
+ Mpp
γm
pn
Mnph + pn
, (11)
f˙ = 0 ⇐⇒ f = m + Fdam
γ f
. (12)
The steady states of the model are the points where all the nullclines intersect.
Substituting Eqs. 11 and 12, m = Nm(p) and f = N f (Nm(p)) into 9 and 10 reduces
the problem to two simultaneous equations for a in terms of p:
a = Np(p) =
(
h(p)
γp p
− 1
) 1
n
, (13)
where
h(p) = Pbp + Ppp p
n
1 + pn
+ Pf p
(
Fdamγm + Mbp + Mpp pnMnph+pn
)n
(γ f γm)n +
(
Fdamγm + Mbp + Mpp pnMnph+pn
)n , (14)
and
a = Na(p) = App p
n
Anph + pn
+ A f p
(
Fdamγm + Mbp + Mpp pnMnph+pn
)n
(γ f γm)n Anf h +
(
Fdamγm + Mbp + Mpp pnMnph+pn
)n . (15)
The intersections of Np(p) and Na(p), given by Eqs. (13) and (15), give the steady
states, although analytical solutions are in general not tractable. The forms of Eqs. (13)
and (15) mean that they will always intersect at least once, so the system will always
have at least one steady state. With a Hill coefficient of n = 1, Eq. (15) increases
monotonically and Eq. (13) decreases monotonically, giving only one possible steady
state. For n > 2, the nullclines take a similar form aswith n=2, although the parameter
values differ and the steeper gradients allow for the possibility of additional steady
states, in smaller regions of parameter space. For this reason we focus on the case
n = 2 as in our previous work, Baker et al. (2013), through the rest of this analysis.
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(a) (b)
(c) (d) (g)
(e) (f)
Fig. 2 Possible forms of the Np(p) and Na(p), whose intersections define steady states of the OA-model
[Eqs. (5)–(8)]. a, b Schematic representation showing how Na(p) can be sigmoidal (a) or double-sigmoidal
(b). c–f Np(p) can take several forms that may meet the p-axis one (c, e, f) or three (d) times. g A specific
example showing both Np(p) and Na(p) which cross five times, using the parameters Pbp = Mbp =
0.01, Ppp = Pf p = App = Mpp = 10, A f p = 3.2, Aph = Mph = 1, A f h = 0.2, γp = γ f = γm = 1
and Fdam = 0
The first term in Eq. (15) is a Hill function of p and the second is a Hill function of
p embedded within another Hill function. This allows Na(p) to take two qualitative
forms, either a sigmoidal shape, if Aph and A f h are close in value (Fig. 2a), or a
double sigmoidal shape if Aph and A f h are sufficiently different (Fig. 2b).
Equation (13) is only valid when h(p) ≥ γp p. Since h(0) > 0 (for positive basal
production), as limp→∞ h(p)γp p and h(p) is continuous, Np(p) always meets the p-axis
for a large enough value of p.
The function h(p), similar to Eq. (15), can have either a sigmoidal or double
sigmoidal shape. The double sigmoidal shape is possible when the terms involv-
ing Ppp and Pf p are sufficiently different. This leads to several possible shapes of
a = Np(p) =
√
h(p)
γp p
− 1. These are illustrated qualitatively in Fig. 2(c–f).
It is clearly possible for these curves to also intersect three times. We have found
a maximum of five (see Sect. 3.5) with the Hill coefficients of n = 2 but could
conceivably have more. Two or four steady states will only occur when the curves
meet tangentially. Since this only occurs at bifurcations we will focus on cases with
one, three or five steady states.
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Due to the difficulties of obtaining measurements of cytokine levels and rates both
in vivo and in vitro, there is little data concerning the parameters in the model. We
therefore chose an illustrative initial parameter set, summarised in Table 1, in which
similar processes have similar rates and concentration dependence, in the absence of
data suggesting otherwise. The relative thresholds in Hill functions (Aph, A f h, Mph)
are all set to one, equal to the dimensionless thresholds for pro-inflammatory cytokine
regulation in Eq. 5. Similarly, the relative degradation rates (γp, γm, γ f ) are equal
to the dimensionless degradation of a. We set all the cytokine and MMP produc-
tion parameters (Ppp, Pf p, App, A f p, Mpp) to 10 and background rates (Pbp, Mbp)
to 0.01 in order that regulated production is relevant and not dominated by back-
ground rates. These choices avoid unnecessary bias in the network. In the following
sections we consider parameter variations about this initial set in order to uncover
the relevant biologically plausible behaviours to be expected from the system. Vari-
ations reasonably close to this reference parameter set show the range of behaviours
that the model can display. These can be classified into four robust behaviour groups:
homoeostasis, bistable inflammation, tristable inflammation and persistent inflamma-
tion. These groups may better align to individuals clinical manifestation of the disease
and we propose that the behavioural group would be the determinant for long term
prognosis.
With these parameters the system is bistable with three steady states: S0, S1 and S2.
When the levels of p are low, as at S0,which is stable, we assume this would indicate
a quiescent steady state, where cells are producing only the basal level of p necessary
for homoeostatic matrix turnover. The stable limit cycle around the unstable state S2
is likely to indicate an inflamed state due to high and fluctuating levels of p and f .
A projection of the phase-space for this system is shown in Fig. 3a, b, with the latter
showing the steady states in more detail. The diagrams suggest that the stable inflamed
0
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Fig. 3 For the reference parameter set (Table 1), the OA model has a stable quiescent state and a stable
inflamed limit cycle. The figure shows a projection of the phase space for the reference parameter set
(Table 1), showing trajectories for the cartilage model [Eqs. (5)–(8)] for various regularly spaced initial
conditions in (p, a,m) space. a Shows all three steady states whilst, b focuses on the behaviour around the
quiescent steady state. The black circles show the position of unstable fixed points and the red dot shows
the stable fixed point. The trajectories either move to the stable fixed point or the stable limit cycle which
surrounds an unstable fixed point. The unstable steady state influences the path taken by trajectories (colour
figure online)
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limit cycle has a large basin of attraction whilst the quiescent steady state has only a
small basin of attraction.
A sensitivity analysis of small parameter changes around the reference parameter
set gives some insight into the behaviour of the system. Figure 4 shows sensitivity of the
parameters to changes of up to±30% as measured by three features: the concentration
of p at the steady state, the amplitude and the period of any limit cycles. We use a one-
at-a-time sensitivity analysis to measure the sensitivity gain for each feature according
to the sensitivity function,
Sφk =
δφ/φ
δk/k
, (16)
where φ is the feature beingmeasured and k is the parameter being changed.We repeat
this for 1000 iterations choosing a uniformly distributed random percentage change
each time within the range [−30%, 30%]. Parameters related to anti-inflammatory
cytokine production (App, Aph, A f p, A f h) and clearance rate parameters (γp, γm, γ f )
are consistently the most sensitive when the system is at the inflamed state. This sug-
gests that if we alter these parameters from the reference parameter set we may have
significantly different behaviour. For the parameters Pf p, App and A f h the sensitivity
coefficient is negative indicating that increases in these parameter values lead to a
smaller limit cycle amplitude. Whereas, for the other sensitive parameters the coef-
ficient is positive hence an increase in these parameters leads to a larger limit cycle
amplitude. At the quiescent state the system is generally robust to parameter changes
up to ±30% with the exception of changes to γp which can move the system from
the quiescent to the inflamed state with parameter changes within this range. We will
consider this in Sect. 3.6.
3 Bifurcation analysis
In this sectionwe examine the behaviour of the steady states as we vary the parameters.
In the limit when Mbp = 0 and Mpp = 0, this model reduces to the cytokine-only
model of Baker et al. (2013). Figure 5 shows bifurcation diagrams for the parame-
ters which are present in both models, with Mbp = 0 and Mpp = 0. Here we can
see how changes to the cytokine-related parameters can result in transitions between
homoeostasis and inflammation without any mechanical component. Throughout this
section we will compare the current model with the cytokine-only model to see the
effect of fibronectin-mediated feedback.
Since there are fourteen parameters in this model, we focus on those parameters that
we believe may have a bearing on OA initiation and progression. Pro-inflammatory
cytokine production (Pbp, Ppp, Pf p), MMP production (Mbp, Mpp), Fn-fs produc-
tion (Fdam) and Fn-fs clearance (γ f ) have all been implicated in disease progression
and are considered potential treatment targets (Pearle et al. 2005; Homandberg et al.
1998; Martel-Pelletier et al. 2008). The remaining parameters, those relating to anti-
inflammatory production, cytokine andMMP clearance and half maximal parameters,
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Fig. 4 Parameters related to anti-inflammatory cytokine production are particularly sensitive. Box-plots of
the sensitivity of steady state pro-inflammatory cytokine (p) and the period and amplitude of limit cycles,
to variations in model parameters. The top row shows sensitivity at a quiescent state whilst the bottom row
shows sensitivity at an inflamed state. Boxes show the interquartile range (IQR) of the relative sensitivity
coefficient as the parameters are varied randomly from a uniform distribution within the range [−30%,
30%] (n=1000). A value of 1 is representative of an equal change in the feature for a given change in the
parameter
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(a) (b)
(c)
(e)
(d)
Fig. 5 Bifurcation diagrams of the cytokine only model differentiate cytokine-driven from fibronectin-
driven effects. Bifurcation diagrams of the cytokine-only model, (Baker et al. 2013), using the reference
parameter values used in this paper showing the transitions from monostable to bistable. This model does
not have any fibronectin involvement so comparison of a, b with Figs. 6a, b and c, d, e with 10a, c, e
respectively, shows the effect of the fibronectin fragment driven feedback
are discussedmore briefly,with figures in the “Appendix”, sincewe are not considering
these as possible treatment targets.
Henceforth, we use the level of p as a measure of whether an individual is in
a quiescent or inflamed state. A quiescent state, with low p, would indicate that
either (i) an individual is healthy and shows no signs of OA or (ii) an individual
has OA but the disease is not actively progressing at that time (i.e. the individual
is not in a period of flare up). An inflamed state, with high p, would indicate that
cartilage is being actively degraded and there is at least sub-clinical inflammation,
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Table 2 Summary of the behaviours that arise for different values of the parameters in system (5)–(8)
Name No. steady states Stability of steady states Limit cycles Type
Ai 1 SS0 – Homoeostasis
Aii 1 SS0 – Persistent inflammation
Aiii 1 SU0 L
S
1 Persistent inflammation
Bi 3 SS0 , S
U
1 , S
U
2 – Homoeostasis
Bii 3 SU0 , S
U
1 , S
S
2 – Persistent inflammation
Biii 3 SS0 , S
U
1 , S
S
2 – Bistable
Ci 3 SS0 , S
U
1 , S
U
2 L
S
1 Bistable
Cii 3 SU0 , S
U
1 , S
S
2 L
S
1 Bistable
Ciii 3 SS0 , S
U
1 , S
S
2 L
S
1 Bistable
Civ 3 SS0 , S
U
1 , S
S
2 L
U
1 , L
S
2 Bistable
Cv 3 SU0 , S
U
1 , S
U
2 L
S
1 Persistent inflammation
Di 3 SS0 , S
U
1 , S
S
2 L
U
1 , L
S
2 Bistable
Dii 3 SS0 , S
U
1 , S
U
2 L
S
1 , L
U
2 Bistable
Diii 3 SU0 , S
U
1 , S
S
2 L
U
1 , L
S
2 Bistable
Ei 5 SS0 , S
U
1 , S
S
2 , S
U
3 , S
S
4 – Tristable
Eii 5 SS0 , S
U
1 , S
U
2 , S
U
3 , S
S
4 – Bistable
Fi 5 SS0 , S
U
1 , S
U
2 , S
U
3 , S
S
4 L
S
1 Tristable
Fii 5 SS0 , S
U
1 , S
S
2 , S
U
3 , S
S
4 L
U
1 Tristable
The abbreviation S means Stable and U means Unstable, indicating the stability of the steady state or limit
cycle
but would not necessarily indicate clinically observable levels of inflammation. In
this model we see four classifications of behaviour: homoeostasis, where we have
only a quiescent state and any trajectories perturbed away from this state will return;
persistent inflammation where we have only an inflamed state; bistable inflammation
and tristable inflammation. In the multi-stable cases, we have both a quiescent and
either one or two inflamed states, and, given appropriate perturbation in the model,
transitions between the states can occur. A summary of behaviour types found in the
model can be found Table 2.
3.1 Loss of the quiescent steady state
Since the quiescent steady state of the system occurs only when all the variables are
small we can simplify the system [Eqs. (5)–(8)] to analyse the loss of this steady state.
To find the leading order terms of Eq. (5) around the reference parameter set we rescale
all the parameters using the small parameter  where  ∼ 0.01 such that all the hatted
parameters are O(1). If a is small we lose the anti-inflammatory inhibition term since
it is approximately 1. Additionally, if f is small Eq. (8) is a quadratic in p, hence
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Eq. (5) in the limit when all the variables are small, becomes,

d p̂
dt
= P̂bp + 
2
√

̂Ppp p̂
2 + 
3
√

̂Pf p̂Mpp
2
γ̂m
2γ̂ f
2
̂Mph
4 p̂
4 + 22̂Pf p̂Mbp̂Mpp
γ̂m
2γ̂ f
2
̂Mph
2 p̂
2
+ 22̂Pf p̂Mpp ̂Fdam
γ̂m γ̂ f
2
̂Mph
2 p̂
2 − γ̂p p̂ + 
2
√

̂Mbp
2
̂Pf p
γ̂m
2γ̂ f
2
+ 2
2
√

̂Pf p̂Mbp ̂Fdam
γ̂m γ̂ f
2 +
2√

̂Pf p ̂Fdam
2
γ̂ f
2 = 0, (17)
where,
p =  p̂, f = ĥ, Pbp =  P̂bp,
Ppp =
̂Ppp√

, Pf p =
̂Pf p√

, Mbp = ̂Mbp,
Mpp =
̂Mpp√

, Mph = ̂Mph, Fdam =  ̂Fdam,
γp = γ̂p, γm = γ̂m, γ f = γ̂ f = 0.
Taking leading order terms (O()) and next order terms (O(2/
√
)) we have,
dp
dt
=̂Ppp p̂2 − γ̂p p̂ + P̂bp +
̂Mbp
2
̂Pf p
γ̂m
2γ̂ f
2 +
2̂Pf p̂Mbp ̂Fdam
γ̂m γ̂ f
2
+
̂Pf p
̂F2dam
γ̂ f
2 = 0 (18)
The discriminant of (18) determines where we switch from two roots to zero roots,
which represents the loss of the small amplitude steady state. Hence we will lose the
quiescent state if
γ̂p <̂Ppp
⎛
⎝P̂bp + ̂Mbp
2
̂Pf p
γ̂m
2γ̂ f
2 +
2̂Pf p̂Mbp ̂Fdam
γ̂m γ̂ f
2 +
̂Pf p
̂F2dam
γ̂ f
2
⎞
⎠ . (19)
This shows that reducing clearance rates (γm or γ f ) or increasing production rates
(Pbp, Pf p, Mbp or Mpp) is likely to lead to inflammation. Mechanical damage is a
key driver in moving the system towards inflammation, since the parameter Fdam
appears in two terms. In the absence of mechanical damage, cytokine- and fragment-
driven feedback are key to driving the system to inflammation. Referring back to the
network diagram, Fig. 1, this indicates that where we do not have mechanical damage,
the cytokine-only feedback loops will dominate system behaviour and drive the move
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from quiescence. However, if we havemechanical damage, theMMP- and fibronectin-
driven feedback loops become much more important and can become disease drivers
even where the cytokine feedback parameters are at basal levels.
Decreases in γp the left-hand side of the inequality [Eq. (19)] push the system
towards inflammation. However, the clearance rate of p is determined by the half-
life of the pro-inflammatory cytokines, which is unlikely to vary either with time or
between individuals, so is unlikely to be a driver of inflammation in most cases.
3.2 Pro-inflammatory cytokine production parameters
The parameters Pbp, Ppp and Pf p govern the production of pro-inflammatory
cytokines. These cytokines are raised in OA and this has been implicated in disease
progression (Hedbom and Huselmann 2002). The mechanism by which these raised
levels occur is unclear but could be the result of higher than normal production rates
of pro-inflammatory cytokines. If any of these three parameters are sufficiently high,
bistability is lost via a fold bifurcation, and there is a single steady state (Fig. 6).
(a) (b)
(c)
Fig. 6 Increases in pro-inflammatory cytokine production lead to persistent inflammation. Bifurcation
plots of the pro-inflammatory cytokine level (p) against pro-inflammatory cytokine production parameters
a Pbp , b Ppp and c Pf p . The blue dotted lines represent the minimum, maximum and average values of
the limit cycles. The vertical black dashed lines denote the transition between different behaviours, which
are labelled and summarised in Table 2 (colour figure online)
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For intermediate Pbp and Ppp values, the loss of bistability is followed by a single
stable limit cycle (Fig. 6a, b), representing an oscillatory inflamed state. Then at higher
levels of these parameters this is lost, via a Hopf bifurcation, leaving a single stable
steady state. For increases in Pf p, the Hopf bifurcation is encountered before the fold
bifurcation, giving rise to two stable steady states for some values of Pf p. For low
values of Pf p, we can have a single quiescent steady state representing homoeostasis.
As the limit cycle collides with S1 at a homoclinic bifurcation it leaves only one stable
and two unstable steady states. Examination of the phase space suggests that, as for
the reference parameter set, the basin of attraction of the inflamed state is large in the
bistable region and remains large even as we move towards the homoclinic. Even in
the homoeostasis region, trajectories undergo large fluctuations in p before settling to
the quiescent state. One interpretation of these large basins of attraction is that major
deviations from the state of quiescence due to trauma or infection are likely to move
an individual to a state of inflammation, since the large basins for inflammation persist
over the range of small parameter variations, which wemight expect to see in different
individuals. Even in homoeostasis large perturbations to the system take a long time
to resolve, during which some tissue damage may accumulate. This behaviour may
point to the reason for OA being so prevalent since the system trajectories deviate
from the quiescent steady state for wide ranges of parameters and initial conditions.
Comparison of Fig. 5a, b (cytokine-only dynamics) with Fig. 6a, b shows similar
behaviour. One important difference, however, is that both Pbp and Ppp in Fig. 6 show
oscillatory behaviour whereas the inflamed states are fixed points in the cytokine-
only model. If a fixed inflamed state is clinically preferable to an oscillatory one, for
example if this was less symptomatic for patients, the model suggests that inhibition
of fragment-driven feedback may be a justifiable treatment aim.
3.3 MMP production parameters
The parameters Mbp and Mpp determine the maximum rates of MMP production.
Since MMP levels are known to be raised in OA these parameters are of great interest.
Figure 7 shows that, for variations in these parameters about the reference parameter
set, there are no regions of homoeostasis. At high levels of MMP production, with
either highMbp orMpp, there is a region of persistent inflammationwith a stable steady
state. In both cases, at lower production levels, including the reference parameter set, a
fold bifurcation leads to bistability with the introduction of stable and unstable steady
states, providing the possibility of moving to a quiescent state. For Mpp (Fig. 7b),
within the bistable region there is a region of oscillatory inflammation due to two
Hopf points.
For this parameter set, for an individual in an oscillatory inflamed state, an increase
in MMP production pushes the system to a steady inflamed state in which p is lower
than the average of the limit cycle in the oscillatory states. However, the level of f
is lower at smaller values of Mpp so the lower levels of p do not necessarily imply
less cartilage degradation. This counter-intuitive result arises from the balance in the
positive and negative feedback pathways. Mpp is part of both pathways and for the
reference parameter set the negative feedback is dominant. If we make the negative
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(a) (b)
Fig. 7 High rates of MMP production lead to persistent inflammation. Bifurcation diagrams of pro-
inflammatory cytokine level (p) against the MMP production parameters Mbp and Mpp . The blue dotted
lines represent the minimum, maximum and average values of the limit cycles. The vertical black dashed
lines denote the transition between different behaviours, which are labelled and summarised in Table 2
Fig. 8 The MMP production rate, Mpp , is involved in both negative and positive feedback. Hence, its
bifurcation behaviour is dependent on the parameter set. Reduced fibronectin driven anti-inflammatory
cytokine production allows the positive feedback pathway to dominate, hence increases in Mpp lead to
higher values of p at the steady state. Bifurcation diagram of pro-inflammatory cytokine level (p) against
the MMP production parameter Mpp . The value of A f p is reduced from 10 (seen in Fig. 7b) to 2 whilst all
other parameters are the same as in the reference set. The vertical black dashed lines denote the transition
between different behaviours, which are labelled and summarised in Table 2
feedback weaker, by reducing the value of A f p, the positive pathway dominates, and
the value of p at the steady state increases with higher values of Mpp as illustrated in
Fig. 8.
3.4 Fibronectin fragment related parameters
Fibronectin fragments have been shown to exacerbate cartilage degradation in OA
(Homandberg 1999). Fibronectin levels in the model are directly influenced by a
source parameter, Fdam , and a sink parameter, γ f .
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(a) (b)
Fig. 9 a Increased rates of fibronectin clearance, γ f , can move the system from persistent inflammation, b
increased damage, Fdam , has the opposite effect. Bifurcation plots of the pro-inflammatory cytokine level
(p) against the mechanical damage and clearance parameters, γ f and Fdam . The blue dotted lines represent
the minimum, maximum and average values of the limit cycles. The dashed lines denote the transition
between different behaviours, which are labelled and summarised in Table 2 (colour figure online)
The bifurcation plot for γ f , the clearance rate of Fn-fs (Fig. 9a), shows persistent
inflammation for low γ f and bistability for higher γ f . The bistable region is divided
into an oscillatory inflamed state and a steady inflamed state. The value of p at the
steady state lies within the range of the oscillatory behaviour so it is not clear which
behaviour type would be most destructive to the cartilage. These bifurcations suggest
that increasing Fn-fs clearance in an individual could be beneficial, possibly improving
the outcome of treatment to reduce cytokine levels since increasing γ f can move the
system from persistent inflammation to bistability. This is of particular interest since
research has suggested that Fn-fs clearance may be affected by mechanical loading
such as exercise (Evans and Quinn 2006; Zhang and Szeri 2005; O’Hara et al. 1990).
Additionally, γ f principally represents removal of Fn-fs from the ECM via diffusion,
which is likely to be reduced by the changes in the joint that are seen in OA, e.g.
increased water content and immobility.
Mechanical damage is considered to be a major risk factor in OA and the first
stage of repair after mechanical damage to the cartilage is necrosis of the damaged
tissue which leads to increased concentrations of Fn-fs. We represent mechanical
damage to the cartilage by an increase in the Fn-fs production rate, Fdam . Since
Fdam was zero in the reference parameter set, there is bistability at Fdam = 0 as
before (Fig. 9b), which we might associate with the situation in normal cartilage. This
behaviour has been observed in experimental work by Homandberg et al. (1997), who
found that in normal cartilage tissue IL-6 levels became raised after treatment with
high Fn-fs, and remained high over a period of 28days. In contrast, for lower concen-
trations of Fn-fs the levels of IL-6 remained close to the control levels, suggesting a
bistable system. As Fdam increases, a fold bifurcation removes the lower two states
leaving only persistent inflammation. This has not yet been shown experimentally.
However repeating the experiments of Homandberg et al. (1997) with OA cartilage
tissue may provide evidence of a behavioural change, and cytokine levels would be
raised.
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For the reference parameter set damage leads to sustained inflammation. However,
as Fdam increaseswe see that the level of p at the inflamed state reduces as does the level
of f . These reduced levels still represent inflammation butmay indicate slower disease
progression. That an increase in Fdam could slow disease progression is counter-
intuitive and is likely to be due to dominance of the negative fragment-driven feedback.
3.5 Other model parameters
Bifurcation analyses for the other model parameters are presented in Fig. 10. Anti-
inflammatory cytokines reduce the production and activation of pro-inflammatory
cytokines and hence we expect that higher values of App and A f p, the anti-
inflammatory cytokine production parameters, would lead to quiescence. Fig. 10a,
b show that high levels of either parameter result in the loss of the inflamed state and
a return to homoeostasis. This suggests that increases in anti-inflammatory cytokine
production could be beneficial and lead to reduced or even halted cartilage degradation.
Where there is an oscillatory inflamed state (Fig. 10b) decreases to anti-inflammatory
production,move the system to a fixed inflammatory state at a lower value of p than the
maximum of the inflamed limit cycle which may be beneficial depending on the rela-
tionship between cytokine level and cartilage destruction. Comparing Fig. 10a with
the cytokine-only diagram (Fig. 5c), the bistable region occurs over a much wider
range when we have fragment-driven dynamics. In some cases this could mean that
inhibition of fragment-driven feedback could move the system from inflammation to
quiescence.
The parameters Aph and A f h are the concentrations of p and f at which the anti-
inflammatory cytokine production terms are half maximal. As such they represent the
sensitivity of the anti-inflammatory cytokine response to pro-inflammatory cytokine
and Fn-fs stimulation. When either Aph or A f h is small, the anti-inflammatory
cytokine response is maximal at low inputs, and we only have a low single steady
state, indicative of homoeostasis (Fig. 10c, d). At higher values of either Aph or A f h ,
larger concentrations of p or f are required for anti-inflammatory cytokine production,
and there is a fold bifurcation.
Mph governs the sensitivity of MMP production to activation by pro-inflammatory
cytokine. When Mph is small there is a single stable steady state with a high value
of p indicative of persistent inflammation (Fig. 10e). For higher values of Mph we
move to bistability through a fold bifurcation, allowing the possibility of a move to a
quiescent state. The inflamed state is oscillatory for some values of Mph due to two
Hopf bifurcations.
Figure 10f shows that when the clearance of pro-inflammatory cytokines, γp, is
low the steady state is at a high level of p indicating persistent inflammation as might
be expected. When γp is high there is a stable steady state, at low p, indicating
homoeostasis. This implies that inactivation or rapid clearance of pro-inflammatory
cytokines could be effective in halting the disease course of OA.
For this parameter set the bifurcation plots of γm (Fig. 10g) are qualitatively similar
to γ f (Fig. 9a) and show that as as γm is increased the system moves from a persistent
inflammation to bistability, with the possibility of a quiescent state.
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(a) (b)
(c) (d)
(e)
(g)
(f)
Fig. 10 Model parameters go through bifurcations as their values are varied. Bifurcation plots of pro-
inflammatory cytokine level (p) against parameters App, A f p, Aph , A f h , Mph , γp and γm . The blue
dotted lines represent the minimum, maximum and average values of the limit cycles. The black dashed
lines demarcate regions of different behaviour types listed in Table 2
3.6 Tristable parameter values
Single parameter variations from the reference set showed at most 3 steady states, so
we altered the parameter set to see if five-state behaviour emerged as is suggested by
our analysis of the nullclines in Sect. 2. The local sensitivity analysis revealed that
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Fig. 11 A small region with five steady states emerges as a result of Hopf and fold bifurcations. Two
parameter bifurcation diagram showing curves of the Hopf and fold bifurcations in A f p–A f h space, for
the reference parameter set. The diagram shows that if we reduce the value of both A f p and A f h from
the values of the reference set there is a region where there are five steady states as a result of fold and
Hopf bifurcations (shown as dashed blue and solid green lines respectively). A homoclinic bifurcation is
shown in dotted black, which emerges from a Bogdanov–Takens bifurcation (labelled BT). Cusp points are
labelled CP (colour figure online)
anti-inflammatory cytokine production parameters are the most sensitive. Figure 11
shows that five states emerge as a result of fold bifurcations as A f p and Aph are
varied together. Where the Hopf and fold bifurcations meet there is a Bogdanov–
Takens bifurcation point (Bogdanov 1981). From this point the homoclinic bifurcation
emerges between the fold and Hopf bifurcations.
At A f p = 3.2 and A f h = 0.2 there are five steady states (Fig. 11), with two stable
steady states and a stable limit cycle. As a result of the smaller value of A f p the
maximum rate of anti-inflammatory cytokine feedback is lower than for the reference
parameter set. However, a smaller A f h means the fragment-driven anti-inflammatory
cytokine production may be stronger when levels of f are low. Tristability may be
important for OA treatment since a move from one inflamed state to a less destructive
one could slow the disease course where movement to a quiescent state is not possible.
This will be discussed further in Sect. 4.
Figure 12 shows bifurcation plots for single parameter variations of Pbp, Ppp, Pf p,
Mbp, Mpp, Fdam and γ f from this new parameter set. Comparing the plots in Fig. 12
to those of the reference parameter set (Fig. 6a), for Pbp we see a reduced range of
oscillatory behaviour and persistent inflammation occurs at lower values of Pbp. The
bifurcation plot of Ppp, Fig. 12b, shows that homoeostasis emerges when A f p and
A f h are lower, compared to Fig. 6b. As with Pbp the range over which oscillatory
inflammation occurs is much reduced. Pf p variation (Fig. 12c) changes little from the
bifurcations in the reference parameter set (Fig. 6c).
Bistability persists at high values of Mbp when A f p and A f h are lower (Fig. 12d),
however the levels of p in both states are high and suggest differing intensities of
inflammation rather than quiescence and inflammation. The plot for Mpp (Fig. 12e)
compared to that of the reference parameter set (Fig. 7b), shows additional fold bifur-
cations in the upper branch. Additionally the limit cycle branches now collide with
unstable branches at homoclinic bifurcation points. This has a significant effect as
123
M. Baker et al.
(a) (b)
(c) (d)
(e) (f)
(g)
Fig. 12 For some parameter ranges, one parameter variations showmono-, bi- and tri-stability. Bifurcation
diagrams for Eqs. (5)–(8) in a parameter region with five steady states. Pro-inflammatory cytokine level
plotted against a Pbp , b Ppp , c Pf p , d Mbp , e Mpp , f γ f and g Fdam . The dashed lines denote the transition
between different behaviours, which are labelled and described in Table 2. The reference parameters, see
Table 1 have been used except A f p = 3.2 and A f h = 0.2
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there is now a region of homoeostasis between two regions of bistability. This is also
seen for γ f . Fdam (Fig. 12g), like Mbp, has a new region of bistability between two
inflamed states.
3.7 Robustness of behaviour groups
Our analysis so far of one- and two-parameter variations has revealed behaviours that
fall into four groups: homoeostasis, bistability, tristability and persistent inflammation.
The manifestation of OA in individual patients may be determined by the specific
behaviour type within one of the four groups, for example persistent inflammation that
is steady or oscillatory. To further demonstrate robustness of the behaviour groups,
in Fig. 13, we show additional two-parameter bifurcation studies for Ppp varying
along with each of Pf p, App, A f p, Mpp and γ f . When Ppp is low we generally have
bistability,with disease occurring at higher levels of Ppp , so that this parameter is likely
to be important in OA initiation and progression,regardless of the other parameters.
As in Fig. 11, we again see a co-dimension 2 Bogdanov–Takens bifurcation, at
which fold andHopf bifurcations collide.Close to this point, a limit cycle connectswith
one of the two steady states, resulting in the loss of the limit cycle to a homoclinic orbit
(Izhikevich 2006).Often in the vicinitywe also have aGeneralisedHopf (GH) point (or
Bautin bifurcation)where theHopf switches fromsubcritical to supercritical. These are
an important feature of the system as they change the nature of persistent disease from
fixed to oscillatory or vice versa. There is no clinical evidence of oscillatory behaviour
in OA, however, anecdotal evidence of patient experience (Hawker et al. 2008; Allen
et al. 2009) suggests this is a possibility. We include two parameter bifurcation plots
for the other combination of the six parameters in Fig. 13 in “Appendix 2”.
All of these bifurcation analyses demonstrate that the four key types of behaviour
(homoeostasis, persistent inflammation, bistability and tristability) are robust core
features of the system. In the next sectionwewill consider possible treatment strategies
for each of these behaviour groups.
4 Treatment strategies
Clinical trials of disease modifying drugs for OA have not shown a slowing down of
disease progression, as measured by pain, inflammation and joint space, or have had
unexpected complications. Here we consider two of the main treatments that have
reached clinical trials, anti-cytokine drugs and MMP inhibitors, as well as a further
theoretical treatment possibility Fn-fs inhibition. Anti-cytokine therapy, licensed for
use in RA, inhibits either the production or functioning of pro-inflammatory cytokines,
usually TNF-α. We model this as an instantaneous reduction in the level of pro-
inflammatory cytokine, p. Additionally we consider an anti-cytokine therapy which
instantaneously increases the level of anti-inflammatory cytokine, a. This type of
treatment is licensed for RA but trials for OA have been unsuccessful (Chevalier et al.
2009). We model the effect of MMP inhibitors as an instantaneous reduction of m.
In addition to these three types of therapies we also consider the possibility of Fn-fs
as a target for OA treatment and model this as a reduction in the level of f . Here we
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Fig. 13 Two parameter bifurcation analysis showing robustness of the model [Eqs. (5)–(8)] behaviour to
parameter variations. Two parameter bifurcation diagrams showing Ppp against Pf p, App, A f p, Mpp and
γ f . Fold bifurcations are shown as blue lines and Hopf bifurcations as green lines. Areas of homoeostasis,
bistability and persistent inflammation are indicated. The reference parameters in Table 1 have been used
(colour figure online)
consider how persistent inflammation, bistable and tristable behaviours may respond
to these treatments.
4.1 Treatment for bistable cases
In the bistable case (as in the reference parameter setwe consider here) it is theoretically
possible for an individual in an inflamed state to be moved to a state of quiescence,
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(a)
(b)
Fig. 14 Monotherapy treatments are unable tomove the system to quiescence, but combined treatments can
be effective. a Time course simulations of single treatments where the system displays bistable behaviour.
At t = 0 the system is at the disease limit cycle. A single dose of anti-cytokine (reduction in p), MMP
inhibition (reduction in m) or Fn-fs inhibition (reduction in f ) treatment was simulated at t = 20. The
dose size given in each case was the maximum possible (i.e. an instantaneous decrease to zero of each
of the variables). b Time course simulations of combined treatments where we have bistable behaviour in
the system. A single combined dose of anti-cytokine, MMP inhibition and Fn-fs inhibition treatment was
simulated at t = 20 and t = 16. The dose size is the minimum dose size (see text) that moves the system to
health [0.2(p), 0.5(m) and 0.4( f )]. The diagrams show that dose timing as well as dose size is important.
The reference parameter set was used for these simulations
and this should be the aim for disease-modifying treatment, to achieve the best clinical
outcome.
In this model, for the reference parameter set, we tried single doses of anti-cytokine
therapy, MMP inhibition and Fn-fs inhibition. In each case we simulated the effect
of applying the largest possible dose by reducing the level to zero, but none of these
treatments moved the system to quiescence (Fig. 14a), since the systemwas not moved
outside the basin of attraction of inflammation. This result is in line with data from
clinical trials of anti-cytokine and MMP inhibition treatments, that have shown no
long term benefit in single dose therapy (Qvist et al. 2008).
We have found that a combined treatment strategy can bring the system to a state of
quiescence. Over several simulations we varied the timing and reduced the magnitude
of the doses used, until we found the smallest dose of each treatment that would move
the system from inflammation to quiescence when all three treatments were combined
(Fig. 14b). In this case the magnitudes of the variable reductions are 0.2(p), 0.5(m)
and 0.4( f ).
Timing of the dose is of crucial importance, particularly for this parameter set since
the inflamed state is oscillatory. If a dose is given at the wrong point in the limit cycle
then it may not be large enough to move out of the basin of attraction of the inflamed
state and may result in a period of increased amplitude oscillations as it moves back
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Fig. 15 Multiple doses of combined therapy allow the individual dose magnitude to be reduced. Time
course simulations of multiple combined treatments where we have bistable behaviour in the system. At
t = 0 the system is at the inflamed limit cycle. Six combined doses of anti-cytokine, MMP inhibition and
fibronectin fragment inhibition treatment are simulated starting at t = 20, with a dose interval of ten time
units. The dose magnitude for each of the six doses is 0.1(p), 0.2(m) and 0.1( f ). The reference parameter
set was used for these simulations
to the inflamed state (Fig. 14b). This type of behaviour could have large implications
both for clinical trial results and treatment regimens for drugs taken to market.
We find that multiple doses of treatment given over time can also reduce the system
to quiescence and allow smaller individual doses to be given. Figure 15 shows a series
of six doses, given ten time units apart, which moves the system to quiescence; the
magnitude of each dose is 0.1(p), 0.2(m) and 0.1( f ). Compared to the single dose
strategy this represents a large reduction in dosage at any particular time. This may
be beneficial if there are side effects associated with the drugs, although overall,
the total amount of drugs given would be higher in this case. As with the single
dose, the timing and size of the dose is important as well as the total number of
doses.
Anti-inflammatory cytokines are not currently used in anti-cytokine therapy as
they have had poor joint response in clinical trials. We found that a single dose of
anti-inflammatory cytokines was able to bring the system to a quiescent state from
the inflamed state. Figure 16 shows that a dose of 40 units moves the system to
quiescence, when given at t=20. This dose is the lowest that will bring the system
to quiescence. However, this dose is an order of magnitude greater than the anti-
inflammatory cytokine level at the inflamed state, so may not be clinically feasible.
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Fig. 16 A high dose of anti-inflammatory cytokines can bring the bistable system to the quiescent state.
Time course simulations of single doses of anti-inflammatory cytokines where we have bistable behaviour
in the system. At t = 0 the system is at the inflamed limit cycle. A dose of 40 units of a is given at t=20
bringing the system to quiescence. The reference parameter set (Table 1) was used for these simulations
Dose timing is not trivial; the optimal timing is not at the highest point of p of the
limit cycle as might be expected, but at the point where the system is closest to the
basin of attraction of the quiescent state. This point may vary between individuals so
individually tailored treatment plans may be necessary for most effective treatment.
We investigated application of multiple doses of anti-inflammatory cytokines in
order to reduce the dose size necessary. By giving 3 doses at intervals of 14 time units
starting at t=20 we were able to bring the system to quiescence with a dose size of
20, reduced from 40 in the single dose case at this time (Fig. 17). Again timing of the
initial dose,the dose interval and number of doses are of crucial importance.
Finally for the bistable case we have considered how an increased rate of Fn-fs
clearance could affect treatment options. Research has shown that clearance of macro-
molecules such as Fn-fs is increased in the cartilage with cyclic loading (Evans and
Quinn 2006), so an increase in γ f alongside reductions in p or m, may be representa-
tive of a course of exercise or physiotherapy in combination with disease-modifying
drugs. Increasing the value of γ f has a similar effect to Fn-fs inhibition and sim-
ulations show that if this is raised we no longer need to alter the amount of f to
bring the system to quiescence (Fig. 18). This may mean that combined anti-cytokine
and MMP inhibition therapy, alongside physical therapy, could be a viable treatment
option.
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Fig. 17 Multiple smaller doses of anti-inflammatory cytokine can move the system to quiescence but dose
timing, interval and size are all crucial to treatment outcome. Time course simulations of multiple doses of
anti-inflammatory cytokines where we have bistable behaviour in the system. At t = 0 the system is at the
disease limit cycle. In the top row three doses of 20 units of a are given as indicated by the black arrows. In
the bottom row five doses of 10 units of a are given as indicated by black arrows. The reference parameter
set (Table 1) was used for these simulations
Fig. 18 An increased rate of Fn-fs clearance can replace Fn-fs inhibition therapy in combined treatment
regimes. Time course simulations of multiple combined treatments where the system displays bistable
behaviour. The first row shows the system with the reference parameter set, whilst the second row shows
the same parameters except that γ f is increased by 15%. At t = 0 the system is at an inflamed limit cycle.
Six combined doses of only anti-cytokine and MMP inhibition treatment are simulated starting at t = 20,
with a dose interval of ten time units. The dose magnitude for each of the six doses is 0.4(p) and 0.4(m)
4.2 Treatment for tristable cases
Where we have tristable behaviour we generally have two inflamed states and one
quiescent state. Simulations of treatment options for this type of behaviour show
that if the system is at either one of the inflamed states it will act as in the bistable
case and can be moved to the quiescent state, with a sufficient number of doses
of combined treatments. Additionally if the system is at the higher inflamed state
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Fig. 19 In the tristable system multiple doses may move the system to quiescence and a reduced number
of doses may move the system to a less inflamed state. Time course simulations of multiple combined
treatments where the system displays tristable behaviour. The first column shows two doses of treatment,
the second column four doses and the third column six doses. The doses of anti-cytokine, MMP inhibition
and fibronectin fragment inhibition treatment are simulated starting at t = 20, with a dose interval of ten
time units. The dose magnitude for each dose is 0.1(p), 0.2(m) and 0.1( f )
it can be moved to the lower inflamed state with fewer doses of treatment than
are required to move the system to quiescence. Figure 19 shows multiple doses of
combined treatments of anti-cytokine, MMP inhibition and Fn-fs clearance thera-
pies. Where two doses are given the system returns to the original inflamed state.
When four doses are given the system moves to a lower inflammatory state, which
in this case is a limit cycle. Six doses are sufficient to move the system to a state of
quiescence.
Figure 20, shows a similar pattern of behaviour for anti-inflammatory cytokine
therapy. For this parameter set much lower doses of a bring about quiescent compared
to the bistable case.
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Fig. 20 In the tristable system multiple doses of anti-inflammatory cytokine bring the system to either a
lower inflamed state or quiescence depending upon the number of doses given. Time course simulations
of multiple doses of anti-inflammatory cytokine where we have tristable behaviour in the system. The first
column shows one dose of treatment, the second column two doses and the third column three doses. The
doses of anti-inflammatory cytokine have a magnitude of 2.5 and are simulated starting at t = 20, with a
dose interval of ten time units. The number of doses determines which state the system is moved to
4.3 Treatment for persistent inflammation
In cases of persistent inflammation moving to a quiescent state is not possible without
parameter changes. However, disease control may still be possible with ongoing doses
of disease modifying drugs (Fig. 21) which can reduce the cytokine and fibronectin
levels to quiescent levels, although this is not self-sustaining. In this case the dose size
required is much higher than that needed in the bistable case, to bring the system to
low cytokine levels.
There is a trade off between dose size and dose interval, with smaller intervals
allowing a decrease in the size of the dose. However, in clinical practice there would
be both medical and practical considerations in reducing dose interval.
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Fig. 21 With persistent inflammation combined therapy can induce quiescence but cessation of treatment
would allow inflammation to return. Time course for the system showing persistent inflammation. Multiple
combined treatments are given ten time units apart starting at time 20. The dose size for the treatments are
0.4(p), 1.2(m) and 1.1( f ) representing a 98%(p), 82%(m) and 75%( f ) reduction from the inflamed state.
These lower the system variables to a quiescent level. Parameters used are the reference parameter set as
described in Sect. 3, except for Pf p = 40
Repeated doses of anti-inflammatory cytokine can also reduce the cytokine and
fibronectin levels. However, the dose size needs to be very high. For this parameter
set a dose size of 500 units, 62 times greater than the inflamed state is required. The
system is also very sensitive to dose size with some smaller dose sizes increasing
the levels of p. The large dose size and sensitivity to change may make this type of
treatment difficult to implement in a clinical setting.
5 Discussion
Osteoarthritis is associatedwith both clinical and sub-clinical inflammation (Hoff et al.
2013; Wojdasiewicz et al. 2014). It is now largely accepted that cytokines, MMPs and
fibronectin fragments are key inflammatory mediators in destructive OAmechanisms.
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Effective disease-modifying therapies are much needed for OA (Qvist et al. 2008;
Conaghan 2013), and these pathways appear to offer good targets. However, the lack
of success in clinical trials suggests that we may not understand sufficiently well
the dynamic interactions of these pathways. To gain a better understanding of the
nature of these dynamics we grouped cytokines by function, either pro-inflammatory
or anti-inflammatory, in addition to MMPs and Fn-fs, simplifying the problem to four
variables.
Inflammatory cytokines may be raised in osteoarthritis as a result of loss of ECM
homoeostasis (Creamer andHochberg 1997). Possible causes of this include increased
numbers of cytokine receptors on chondrocytes, making them more sensitive to up-
regulation (Wojdasiewicz et al. 2014) and over expression of either cytokines orMMPs
as a result of secretory cell senescence where cells over produce cytokines as the result
of genomic damage in aging chondrocytes (Berenbaum 2013). Regardless of cause the
net result is a loss of the homoeostatic balance of ECM turnover. Bifurcation analysis
of the model revealed a range of behaviour types, which in general terms we class as
homoeostasis, persistent inflammation, bistable inflammation or tristable inflamma-
tion. Individuals in the homoeostasis group would not be susceptible to developing
OA, whereas those in the other groups would either be susceptible or have devel-
oped OA. In the cytokine-only model for rheumatoid arthritis (Baker et al. 2013), the
regions of homoeostasis were relatively large and we suggested that many individuals
would, therefore, not be susceptible to RA. However in the OA model presented here,
in the parameter ranges we considered, homoeostasis only accounted for very small
regions in comparison with the other behaviours (Figs. 6, 7, 9, 10, 13). This sug-
gests that most individuals will be susceptible to developing OA, given an appropriate
stimulus. Ageing chondrocytes, and indeed increasing frailty with aging, increase the
likelihood of such a stimulus being sufficient to lead to OA changes. This corresponds
with the aetiology of OA, given the large percentage of affected individuals including
asymptomatic individuals, and the strong association with age.
In the bulk of this paper we have focused on equal Hill coefficients with n = 2 for
all regulatory functions. There is no experimental evidence to indicate what n should
be, or indeed whether all the coefficients should be equal. For equal Hill coefficients
greater than 2 we have very similar qualitative behaviour to n = 2, except for very
small regions of parameter space we have a greater number of steady states. This
can also be the case with mixed coefficients greater than 2. For example, we have
been able to find up to seven steady states with mixed Hill coefficients of 2 and 4.
The only major behavioural change in the system comes when all n = 1, giving a
single steady state which would represent homoeostasis or persistent inflammation,
depending on the value of p (shown in “Appendix 1”). There would be no bifurcation
behaviour in the model and treatment in this case would be as discussed in Sect. 4.3.
We have no reason to believe that the special case of all n = 1 is likely. Our variables
are not single signalling molecules but functional classes and, given the redundancy
in cytokine signalling mechanisms many of these are likely to be up-regulated in
OA simultaneously. Furthermore, the Hill functions represent pathways involving
multiple receptors, and transcriptional regulations which are likely to involve multiple
transcription factors per signalling protein (Begitt et al. 2014). Therefore, it seems
entirely feasible that the case with n ≥ 2 is representative of the in vivo situation.
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Both oscillatory and steady inflammatory states are present in the model. In the
steady case it is likely that such patients would see a gradual increase in inflamma-
tion and disability as a result of consistently high cytokine levels. OA progression
is generally assessed through patient pain score and decreasing mobility. Some OA
patients report intermittent periods of pain in early OA and a pattern of flare ups in
OA is commonly reported (Creamer and Hochberg 1997; Hawker et al. 2008; Maly
and Cott 2009; Allen et al. 2009), which may be a manifestation of the limit cycles
we see in the model, or movement between quiescent and inflamed states as levels of
cytokines, MMPs or Fn-fs fluctuate. This pattern of behaviour in RA has been linked
to cyclic levels of cytokines, and the same may be true for OA, although data is not
yet available for OA. The treatments we apply in this model move the system away
from a disease state, and these treatments will work both in the case of fixed and
oscillatory inflammation. It may be possible, with disease modifying drugs, to move
a patient from an oscillatory inflamed state to a fixed inflammatory state, such as in
the tristable case illustrated in Fig. 20. In this model, we do not examine which type
of inflammatory behaviour is most destructive long term, but it may be possible to
explore this with a spatial model of OA cartilage.
Examination of current research and clinical practice gives insight into potential
treatment strategies. Currently no disease-modifying treatments are available for OA.
Amongst those undergoing clinical review are anti-cytokine and MMP inhibitor ther-
apies. We have considered four different treatment strategies: anti-cytokine therapy,
anti-inflammatory cytokines, MMP inhibitors and Fn-fs inhibitors. We found a com-
bined treatment strategy to be the most effective at treating bistable, tristable and
persistent inflammation. Our model predictions further suggest dose size and timing
are important to treatment outcome and it may be possible to optimise these using con-
trol theory.We found that the only effectivemonotherapywas to use anti-inflammatory
cytokines, although this treatment requires very high dose sizes relative to steady state
concentrations. Treatment outcome is predicted to be highly sensitive to dose timing
and interval since the basin of attraction of the quiescent state is small and local to
the state. These issues may make clinical treatment with anti-inflammatory cytokines,
such as IL-1Ra, infeasible and may explain the failure of IL-1Ra drugs trials (Cheva-
lier et al. 2009), despite promising experimental results which showed the response
to anti-inflammatory therapy in animal models (Caron et al. 1996; Fernandes et al.
1999). For the other three treatment options any one of these alone is predicted to be
ineffective, and combined treatments seem to be necessary (Sect. 4). We can see from
the phase diagram (Fig. 3) why this is the case. Any move from the inflamed state
in only one direction would remain in the basin of attraction of the inflamed state. In
all the parameter sets that we considered the basin of attraction of the quiescent state
was small. Whilst our theoretical model is qualitative in nature, the results suggest
that combined treatments offer a much better possibility of success than single treat-
ments, even where the single treatment shows no benefit alone (Fig. 14). We saw that
in the case of tristability we had an option of treatment to move the system from a
higher inflamed state to that of a lower one. If there were additional inflamed states,
as considered in Sect. 2, it may be possible, in principle, to move an individual from
the higher inflamed state to any of these lower states. However it is unlikely that in
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the foreseeable future we would be able to identify individuals with such multiple
inflamed states or personalise the treatment plan to such a degree.
Some evidence of the feasibility the treatments we have suggested may come from
studies into joint lavage therapy. Although controversial due to mixed results, this
treatment involves flushing an OA joint with saline which is analogous to reducing
the value of variables in the model. Some studies have reported relatively long term
improvements in patients given this treatment (Arden et al. 2008). The varied results
of such treatments with some patients finding it ineffective, corroborates the likely
existence of different disease phenotypes.
Clinical and experimental data could provide validation for this theoretical model.
Lack of data and the difficulty of obtaining data relating to cytokine andMMP dynam-
ics in OA means that the existence of the behaviour dynamics found in this model has
not yet been proven in a clinical or experimental setting. However, studies of cytokine
andMMPexpression inOAhave shown that these are raised both in early and advanced
OA (Scanzello et al. 2009). This suggests the presence of an inflamed state where lev-
els of cytokines and MMPs are raised, in comparison to a quiescent state where they
remain low as predicted by our model. The study of Homandberg et al. (1997) indi-
cates that bistability exists within normal human cartilage, and could be extended to
investigate whether this changes in osteoarthritic cartilage. More experimental work
would need to be conducted in this area to show the difference between early and late
stage OA, which would help identify which type of treatments would be appropriate.
However, since the structure of the cytokine networkwemodel here is well established
(Goldring 2000a; Martel-Pelletier et al. 1999; Tetlow et al. 2001; Sandell and Aigner
2001) we are confident that such states could exist, and hence that treatments of the
types we have theorised are realistic experimental targets. The lack of biomarkers
(easily measurable indicators of disease severity) for OA makes oscillatory behaviour
difficult to track, but periods of flare up are widely reported anecdotally and consid-
ered part of the disease course, particularly in early OA. Associations between these
periods of OAflare up, increasedMMP expression and increased cartilage degradation
have been reported (Manicourt et al. 2005).
Limitations of the model include the lack of a link to clinical disease measures,
which include joint space narrowing and radiographic evidence of cartilage deteriora-
tion. As better measures of OA disease activity are developed, such as OA biomarkers
we may be able to draw more detailed conclusions about OA disease dynamics in
future studies. We have not explored spatial and mechanical aspects of the disease,
which play a large role in OA progression, and have been explored mathematically
by others. In this paper we have explored the behaviour of cytokine interactions in
the joint and identified potential areas of future research into OA treatment strategies.
Although we have been unable to directly validate the model due to a lack of quantita-
tive, comparable experimental or clinical data, we have found that the model mimics
many clinical features of the condition. We believe that future work in this area needs
to combine all these aspects of OA and joint mechanics, as it is becoming increasingly
clear from biological research that the interactions between physical and biochemical
factors in OA are significant.
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Appendix 1: Hill coefficients=1
When the Hill coefficients are all 1 the dimensionless model simplifies to
dp
dt
=
(
Pbp + Ppp p
1 + p + Pf p
f
1 + f
)(
1
1 + a
)
− γp p (20)
da
dt
= App p
Aph + p + A f p
f
A f h + f − a (21)
dm
dt
= Mbp + Mpp p
Mph + p − γmm (22)
d f
dt
= m + Fdam − γ f f. (23)
At steady state we have
a =
(
1
γp p
)
×
⎛
⎝Pbp + Ppp p
1 + p + Pf p
(
Fdamγm + Mbp + Mpp pMph+p
)
(γ f γm) +
(
Fdamγm + Mbp + Mpp pMph+p
)
⎞
⎠ − 1
(24)
Fig. 22 Forms of the p and a
nullclines when the Hill
coefficients=1. The a-nullcline
is monotonically increasing
whilst the p-nullcline is
monotonically decreasing
leading to only one possible
steady state which is stable
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and
a = App p
Aph + p
+ A f p
(
Fdamγm + Mbp + Mpp pMph+p
)
(γ f γm)A f h +
(
Fdamγm + Mbp + Mpp pMph+p
) . (25)
Given that all the parameters must be positive Eq. (24) must be monotonically
decreasing and Eq. (25) must be monotonically increasing (Fig. 22). This allows for
only one steady state, which is always stable. Hence, depending on the value of p at
the steady state, we have either behaviour type Ai (homoeostasis) or behaviour type
Aii (persistent inflammation). Treatments for persistent inflammation are discussed
in Sect. 4.3.
Appendix 2: Additional two parameter bifurcation diagrams
We show here further exploration of the global parameter space by looking at two-
parameter bifurcation diagrams of combinations of parameters Pf p, App, A f p, Mpp
and γ f (Figs. 23, 24, 25, 26).
Fig. 23 Two parameter bifurcation diagrams showing Pf p against App, A f p, Mpp and γ f . Fold bifurca-
tions are shown as blue lines, Hopf bifurcations as green lines and homoclinic bifurcations are shown in
black. Areas ofmonostable health, bistability andmonostable disease are indicated. The reference parameter
set is used (colour figure online)
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Fig. 24 Two parameter bifurcation diagrams showing App against A f p, Mpp and γ f . Fold bifurcations
are shown as blue lines and Hopf bifurcations as green lines. Areas of monostable health, bistability and
monostable disease are indicated. The reference parameter set is used (colour figure online)
Fig. 25 Two parameter bifurcation diagrams showing A f p against Mpp and γ f . Fold bifurcations are
shown as blue lines, Hopf bifurcations as green lines and homoclinic bifurcations are shown in black. Areas
of monostable health, bistability and monostable disease are indicated. The reference parameter set is used
(colour figure online)
123
M. Baker et al.
Fig. 26 Two parameter
bifurcation diagram showing
Mpp against γ f . Fold
bifurcation is shown as a blue
line and Hopf bifurcations as
green lines. Areas of bistability
and monostable disease are
indicated. The reference
parameter set is used (colour
figure online)
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